The global market for mRNA Cancer Vaccines and Therapeutics was estimated to be worth US$ 140.4 million in 2023 and is forecast to a readjusted size of US$ 480.9 million by 2030 with a CAGR of 19.0% during the forecast period 2024-2030

mRNA Cancer Vaccines and Therapeutics - Market

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.

The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.

Report Scope

This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of mRNA Cancer Vaccines and Therapeutics by region & country, by Type, and by Application.

The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.

Market Segmentation

Scope of mRNA Cancer Vaccines and Therapeutics - Market Report

Report Metric	Details
Report Name	mRNA Cancer Vaccines and Therapeutics - Market
Forecasted market size in 2030	US$ 480.9 million
CAGR	19.0%
Forecasted years	2024 - 2030
Segment by Type:	Adeno Carcinomas Mucinous Carcinomas Adenosquamous Carcinomas
Segment by Application	Infectious Disease Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of mRNA Cancer Vaccines and Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of mRNA Cancer Vaccines and Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of mRNA Cancer Vaccines and Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the mRNA Cancer Vaccines and Therapeutics - Market size in 2030?

Ans: The mRNA Cancer Vaccines and Therapeutics - Market size in 2030 will be US$ 480.9 million.

What is the mRNA Cancer Vaccines and Therapeutics - Market share by region?

Ans: Europe is follower, accounting for about 28% market share.

What is the market share of major companies in mRNA Cancer Vaccines and Therapeutics - Market?

Ans: Top 3 companies occupied about 82% market share.

Who are the main players in the mRNA Cancer Vaccines and Therapeutics - Market report?

Ans: The main players in the mRNA Cancer Vaccines and Therapeutics - Market are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology

What are the Application segmentation covered in the mRNA Cancer Vaccines and Therapeutics - Market report?

Ans: The Applications covered in the mRNA Cancer Vaccines and Therapeutics - Market report are Infectious Disease, Cancer, Others

What are the Type segmentation covered in the mRNA Cancer Vaccines and Therapeutics - Market report?

Ans: The Types covered in the mRNA Cancer Vaccines and Therapeutics - Market report are Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas

1 Market Overview

1.1 mRNA Cancer Vaccines and Therapeutics Product Introduction

1.2 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecast

1.3 mRNA Cancer Vaccines and Therapeutics Market Trends & Drivers

1.3.1 mRNA Cancer Vaccines and Therapeutics Industry Trends

1.3.2 mRNA Cancer Vaccines and Therapeutics Market Drivers & Opportunity

1.3.3 mRNA Cancer Vaccines and Therapeutics Market Challenges

1.3.4 mRNA Cancer Vaccines and Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking (2023)

2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies mRNA Cancer Vaccines and Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies mRNA Cancer Vaccines and Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of mRNA Cancer Vaccines and Therapeutics

2.6 mRNA Cancer Vaccines and Therapeutics Market Competitive Analysis

2.6.1 mRNA Cancer Vaccines and Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by mRNA Cancer Vaccines and Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Adeno Carcinomas

3.1.2 Mucinous Carcinomas

3.1.3 Adenosquamous Carcinomas

3.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type

3.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Infectious Disease

4.1.2 Cancer

4.1.3 Others

4.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application

4.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region

5.1.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

5.2.2 North America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

5.3.2 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

5.5.2 South America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value

6.3 United States

6.3.1 United States mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.3.2 United States mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.4.2 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.5.2 China mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.6.2 Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.7.2 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India mRNA Cancer Vaccines and Therapeutics Sales Value, 2019-2030

6.9.2 India mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Moderna Therapeutics

7.1.1 Moderna Therapeutics Profile

7.1.2 Moderna Therapeutics Main Business

7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Moderna Therapeutics Recent Developments

7.2 CureVac

7.2.1 CureVac Profile

7.2.2 CureVac Main Business

7.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 CureVac Recent Developments

7.3 Translate Bio

7.3.1 Translate Bio Profile

7.3.2 Translate Bio Main Business

7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 BioNTech Recent Developments

7.4 BioNTech

7.4.1 BioNTech Profile

7.4.2 BioNTech Main Business

7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 BioNTech Recent Developments

7.5 Sangamo Therapeutics

7.5.1 Sangamo Therapeutics Profile

7.5.2 Sangamo Therapeutics Main Business

7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Sangamo Therapeutics Recent Developments

7.6 Argos Therapeutics

7.6.1 Argos Therapeutics Profile

7.6.2 Argos Therapeutics Main Business

7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Argos Therapeutics Recent Developments

7.7 In-Cell-Art

7.7.1 In-Cell-Art Profile

7.7.2 In-Cell-Art Main Business

7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 In-Cell-Art Recent Developments

7.8 eTheRNA

7.8.1 eTheRNA Profile

7.8.2 eTheRNA Main Business

7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 eTheRNA Recent Developments

7.9 Ethris

7.9.1 Ethris Profile

7.9.2 Ethris Main Business

7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Ethris Recent Developments

7.10 Tiba Biotechnology

7.10.1 Tiba Biotechnology Profile

7.10.2 Tiba Biotechnology Main Business

7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Tiba Biotechnology Recent Developments

8 Industry Chain Analysis

8.1 mRNA Cancer Vaccines and Therapeutics Industrial Chain

8.2 mRNA Cancer Vaccines and Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 mRNA Cancer Vaccines and Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 mRNA Cancer Vaccines and Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. mRNA Cancer Vaccines and Therapeutics Market Trends

Table 2. mRNA Cancer Vaccines and Therapeutics Market Drivers & Opportunity

Table 3. mRNA Cancer Vaccines and Therapeutics Market Challenges

Table 4. mRNA Cancer Vaccines and Therapeutics Market Restraints

Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies mRNA Cancer Vaccines and Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies mRNA Cancer Vaccines and Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of mRNA Cancer Vaccines and Therapeutics

Table 10. Global mRNA Cancer Vaccines and Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Moderna Therapeutics Basic Information List

Table 32. Moderna Therapeutics Description and Business Overview

Table 33. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Moderna Therapeutics (2019-2024)

Table 35. Moderna Therapeutics Recent Developments

Table 36. CureVac Basic Information List

Table 37. CureVac Description and Business Overview

Table 38. CureVac mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of CureVac (2019-2024)

Table 40. CureVac Recent Developments

Table 41. Translate Bio Basic Information List

Table 42. Translate Bio Description and Business Overview

Table 43. Translate Bio mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Translate Bio (2019-2024)

Table 45. Translate Bio Recent Developments

Table 46. BioNTech Basic Information List

Table 47. BioNTech Description and Business Overview

Table 48. BioNTech mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of BioNTech (2019-2024)

Table 50. BioNTech Recent Developments

Table 51. Sangamo Therapeutics Basic Information List

Table 52. Sangamo Therapeutics Description and Business Overview

Table 53. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Sangamo Therapeutics (2019-2024)

Table 55. Sangamo Therapeutics Recent Developments

Table 56. Argos Therapeutics Basic Information List

Table 57. Argos Therapeutics Description and Business Overview

Table 58. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Argos Therapeutics (2019-2024)

Table 60. Argos Therapeutics Recent Developments

Table 61. In-Cell-Art Basic Information List

Table 62. In-Cell-Art Description and Business Overview

Table 63. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of In-Cell-Art (2019-2024)

Table 65. In-Cell-Art Recent Developments

Table 66. eTheRNA Basic Information List

Table 67. eTheRNA Description and Business Overview

Table 68. eTheRNA mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of eTheRNA (2019-2024)

Table 70. eTheRNA Recent Developments

Table 71. Ethris Basic Information List

Table 72. Ethris Description and Business Overview

Table 73. Ethris mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Ethris (2019-2024)

Table 75. Ethris Recent Developments

Table 76. Tiba Biotechnology Basic Information List

Table 77. Tiba Biotechnology Description and Business Overview

Table 78. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Tiba Biotechnology (2019-2024)

Table 80. Tiba Biotechnology Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. mRNA Cancer Vaccines and Therapeutics Downstream Customers

Table 84. mRNA Cancer Vaccines and Therapeutics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. mRNA Cancer Vaccines and Therapeutics Product Picture

Figure 2. Global mRNA Cancer Vaccines and Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. mRNA Cancer Vaccines and Therapeutics Report Years Considered

Figure 5. Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by mRNA Cancer Vaccines and Therapeutics Revenue in 2023

Figure 7. mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Adeno Carcinomas Picture

Figure 9. Mucinous Carcinomas Picture

Figure 10. Adenosquamous Carcinomas Picture

Figure 11. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Infectious Disease

Figure 14. Product Picture of Cancer

Figure 15. Product Picture of Others

Figure 16. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 19. North America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 24. South America mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 25. South America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value (%), (2019-2030)

Figure 29. United States mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 31. United States mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 35. China mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 36. China mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 37. China mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 47. India mRNA Cancer Vaccines and Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 48. India mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 49. India mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 50. mRNA Cancer Vaccines and Therapeutics Industrial Chain

Figure 51. mRNA Cancer Vaccines and Therapeutics Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global RNA and DNA Extraction Kit Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-36Z8348

Wed Apr 17 00:00:00 UTC 2024

Add to Cart

Global DNA Library Preparation Kits Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-5U6259

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Edible Insects Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-20A9325

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global DNA Repair Proteins And Reagents Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-9S9524

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions